Tennessee, USA-based King Pharmaceuticals has announced theconsideration to be paid in its cash tender offer for any and all of its outstanding 10.75% senior subordinated notes, due 2009.
Holders of notes who tendered prior to the expiration time of 5pm Eastern Standard Time on November 27 will receive the tender offer consideration plus the consent payment of $20.00 per 1,000 principal amount of notes. Those who did so after this time will receive only the tender offer consideration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze